NORP
Insilico Medicine and TaiGen sign exclusive licensing deal for AI-designed PHD inhibitor ISM4808 to treat anemia in chronic kidney disease
Insilico Medicine; TaiGen Biotechnology; license agreement; ISM4808; PHD inhibitor; anemia of Chronic Kidney Disease; CKD anemia; AI-driven drug discovery; Pharma.AI; Greater China rights; oral PHD inhibitor; IND clearance; China CDE; generative AI; clinical-stage biotech
NiKang Therapeutics Presents NKT5097: First-in-Class CDK2/4 Dual Degrader at SABCS 2025
NiKang Therapeutics; NKT5097; CDK2/4 degrader; SABCS 2025; cancer therapy; breast cancer
Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial
Roche; giredestrant; breast cancer; hormone receptor-positive; ER-positive; HER2-negative; oral SERD; endocrine therapy; adjuvant therapy; recurrence risk; phase III lidERA trial; disease-free survival; San Antonio Breast Cancer Symposium
Curapath and Cristal Therapeutics Sign Co-Exclusive License of CliCr Bioconjugation Platform
Curapath; Cristal Therapeutics; CliCr Bioconjugation Platform; co-exclusive license; nucleic acid delivery; CDMO; drug delivery
US-Backed Group Reports Success with New Tuberculosis Treatment in Phase 2 Study
tuberculosis; TB Alliance; Phase 2 clinical trial; sorfequiline; SPaL regimen; pretomanid; linezolid; drug-resistant TB; ultra-short regimen; US support; clinical trial results
Eli Lilly Signs Up to $2.6 Billion Deal with South Korean Biotech for RNA Medicine Delivery
Eli Lilly; SanegeneBio; South Korean biotech; RNAi medicines; metabolic diseases; LEAD platform; strategic partnership; cardiometabolic; deal value; pharma news
Nuvalent Shares Positive Phase 1/2 ALK Inhibitor Data Rivaling Pfizer’s Lorbrena in Lung Cancer
Nuvalent; neladalkib; ALK inhibitor; ALKOVE-1 trial; Phase 1/2 data; non-small cell lung cancer (NSCLC); lorlatinib; Lorbrena; FDA; clinical trial; objective response rate; CNS activity
Zimmer Biomet Receives U.S. FDA Clearance for Enhanced ROSA Knee Robotic Technology
Zimmer Biomet; FDA clearance; ROSA Knee; OptimiZe technology; robotic knee replacement; personalized surgical planning
Mikael Dolsten Withdraws Candidacy for Novo Nordisk Board; Bavarian Nordic Chairman Resigns
Mikael Dolsten; Novo Nordisk; board of directors; withdrawal; personal reasons; Novo Nordisk Foundation; board shake-up; Danish pharma; Bavarian Nordic; chairman resignation
Santen Announces Completion of Share Buyback
Santen Pharmaceutical; share buyback; repurchase; equity buyback; shareholder value; Japanese pharmaceuticals; financial management